Contralateral Nephroureterectomy for Renal Transplant Recipients With Unilateral Upper Urinary Tract Transitional Cell Carcinoma: A Report of 12 Cases

Hou, Hongping; Xiao, Jing; Tian, Ye

doi:10.1016/j.transproceed.2012.10.034

Cited by 9 publications

(9 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Radical surgery decreased the possibility of recurrence and cancer-specific mortality 23 , and especially for severe CKD patients there’s no worry about the preservation of renal function. Even in unilateral UTUC patients, a prophylactic contralateral nephroureterectomy was recommended for uremic patients or renal transplant recipients 24 25 . Oncologic control and improved survival should remain the dominant therapeutic goals.…”

Section: Discussionmentioning

confidence: 99%

Characteristics and treatment outcomes of pan-urothelial cell carcinoma: a descriptive analysis of 45 patients

Fang

Liu

et al. 2015

Sci Rep

View full text Add to dashboard Cite

The incidence of pan-urothelial cell carcinoma (panUCC), which refers to the presence of both bilateral (UTUC) and bladder tumor (BT), is relatively low. However, the profile of a panUCC cohort of patients remains to be elucidated. We reviewed the data of consecutive UTUC patients who received treatment at our center from 1999 to 2012. Overall, 45 patients were included in this study, with a median age of 64.5 years. Fourteen patients initially presented with unilateral UTUC, 11 initially with BT, and the remainder with multiple tumors. Patients with UTUC were more likely to manifest higher rates of muscle invasion and larger-sized tumors. Five patients were treated with complete urinary tract exenteration (CUTE), and most patients (73.3%) received combined management with conservative and radical surgery. After a median follow-up of 77 months, 18 patients (40%) died including 15 (33.3%) due to cancer. Higher tumor stage was the only risk factor predictive of worse survival. Nineteen patients experienced local recurrence after conservative surgery. This study indicated that PanUCC involves either synchronous or metachronous presentation of tumors with a high risk of tumor recurrence, progression, and dissemination after conservative surgery.

show abstract

Section: Discussionmentioning

confidence: 99%

Characteristics and treatment outcomes of pan-urothelial cell carcinoma: a descriptive analysis of 45 patients

Fang

Liu

et al. 2015

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Our results showed a high proportion of aristolochic acid exposure (60.4%) and a female predominance (91.7%), which is similar to a previous report of UTUC in Chinese renal transplant recipients. 5,11 Possible explanations for this phenomenon include frequent use of Chinese herbs among women and female susceptibility to aristolochic acid-related renal damage. The most common manifestations of these patients included hydronephrosis with or without positive lesions (70.2%), gross hematuria (50%), and flank pain (29.2%).…”

Section: Discussionmentioning

confidence: 99%

“…Patients who underwent bilateral RNU within 3 months were included in the SBRNU group; or else, they were included in the unilateral radical nephroureterectomy (URNU) group. 5 The detailed surgical method has been described in previous studies. 5,9 Transurethral resection of the bladder tumor was performed in patients with concomitant superficial bladder cancers.…”

Section: Definitions Of Clinical Characteristicsmentioning

confidence: 99%

Bilateral Nephroureterectomy Versus Unilateral Nephroureterectomy for Treating De Novo Upper Tract Urothelial Carcinoma After Renal Transplantation: A Comparison of Surgical and Oncological outcomes

Zhang

et al. 2021

Clin Med Insights Oncol

View full text Add to dashboard Cite

Background: There is currently no consensus on the optimal management of de novo unilateral upper tract urothelial carcinoma (UTUC) in renal transplant recipients. We aimed to compare the surgical and oncological outcomes of simultaneous bilateral radical nephroureterectomy (SBRNU) and unilateral radical nephroureterectomy (URNU) to determine the appropriate surgical method. Methods: Patients who developed de novo UTUC after renal transplantation and underwent surgical treatment at our center were included in the study. Outcomes were compared between the SBRNU group (underwent bilateral RNU within 3 months) and the URNU group using the Mann–Whitney U-test for continuous variables, Pearson’s chi-square test for categorical variables, and the log-rank test for survival data. Results: A total of 48 patients were identified, including 21 and 27 patients in the SBRNU and URNU groups, respectively. Comparison of perioperative data showed that the SBRNU group had a significantly longer operative time ( P < .001) and hospital stay ( P = .040) than the URNU group but no statistically significant difference in the blood loss ( P = .171) and morbidity rate ( P = .798). After a median follow-up of 65 months, the SBRNU group had a significantly longer disease-free survival ( P = .009), longer cancer-specific survival ( P = .032), marginally longer overall survival ( P = .066), and similar intravesical recurrence-free survival ( P = .274) than the URNU group. Conclusions: Our data suggest that SBRNU contributes to improved survival without significantly compromising the perioperative outcomes compared with URNU. SBRNU can be considered a feasible option for de novo UTUC after renal transplantation in specialized centers. Prospective studies should be conducted to further explore the best treatment options for this group of patients.

show abstract

“…Surgical treatment is the first choice for UC and prophylactic bilateral nephroureterectomy is recommended when UTUC is suspected. Our previous study demonstrated that, even without any imaging abnormalities, UC morbidity in the contralateral upper tract was significantly higher (15). Furthermore, mammalian target of rapamycin (mTOR) inhibitor-based and calcineurin inhibitor (CNI)-free regimens are recommended, given that several studies demonstrated that the risk of developing de novo malignancies was significantly higher in a group of patients receiving CNI-based immunosuppression compared with a group receiving mTOR inhibitors (16).…”

Section: Discussionmentioning

confidence: 99%

Chemotherapy for urothelial carcinoma in renal transplantation patients: Initial results from a single center

Zhu

Xiao

Guo

et al. 2015

Molecular and Clinical Oncology

View full text Add to dashboard Cite

The aim of this study was to assess the safety and efficacy of gemcitabine plus cisplatin/carboplatin (GC/GCa) chemotherapy in renal transplantation (RT) patients with urothelial carcinoma (UC). We reviewed the records of 12 RT patients with metastatic or locally advanced UC who received chemotherapy at our institution since January, 2013. All the patients received intravenous gemcitabine (800 mg/m) on days 1, 8 and 15, plus cisplatin (70 mg/m) or carboplatin (area under the curve = 5) on day 2, every 28 days. A total of 10 patients completed all the cycles, while 1 patient discontinued treatment due to disease progression and 1 patient discontinued due to non-medical reasons. In total, 12 patients received a median of four cycles of chemotherapy. The overall response rate was 50% (4/8 cases) in patients with measurable lesions. At the time of the study, 5 patients had succumbed to the disease (overall survival, 9.2 months), while 7 patients remained alive (follow-up time, 13.3 months). The most common toxicities were myelosuppression and gastrointestinal effects. Therefore, the GC/GCa regimen was found to be effective and tolerable in RT patients with UC. However, further studies involving more patients and control groups are required to confirm our results.

show abstract

Contralateral Nephroureterectomy for Renal Transplant Recipients With Unilateral Upper Urinary Tract Transitional Cell Carcinoma: A Report of 12 Cases

Cited by 9 publications

References 10 publications

Characteristics and treatment outcomes of pan-urothelial cell carcinoma: a descriptive analysis of 45 patients

Characteristics and treatment outcomes of pan-urothelial cell carcinoma: a descriptive analysis of 45 patients

Bilateral Nephroureterectomy Versus Unilateral Nephroureterectomy for Treating De Novo Upper Tract Urothelial Carcinoma After Renal Transplantation: A Comparison of Surgical and Oncological outcomes

Chemotherapy for urothelial carcinoma in renal transplantation patients: Initial results from a single center

Contact Info

Product

Resources

About